BCRX BioCryst Pharmaceuticals Inc.

+0.3  (+3%)
Previous Close 8.7
Open 8.69
Price To Book 13.64
Market Cap 986769396
Shares 109,641,044
Volume 513,467
Short Ratio
Av. Daily Volume 708,673

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved September 21, 2017.
RAPIVAB (peramivir injection)
Acute uncomplicated influenza to pediatric patients
Phase 2 data to be presented February 23, 9:45 a.m. PT at AAAAI meeting.
BCX7353 - ZENITH-1
Angioedema attacks in patients with hereditary angioedema (HAE)
Phase 3 data due 2Q 2019.
BCX7353 - APeX-2
Reduce or eliminate attacks in HAE patients
Phase 2b data released February 2016 - primary endpoint not met
BCX4161 - OPuS-2
Hereditary angioedema
Approved Dec 22 2014
RAPIVAB (peramivir)
Dosing of first patient in long-term safety trial announced February 28, 2018.
BCX7353 - APeX-S
Hereditary angioedema (HAE)
Phase 1 trial initiation announced January 2, 2019.
Healthy volunteers

Latest News

  1. BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4
  2. The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings
  3. Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
  4. Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries — What Drives Growth in Today's Competitive Landscape
  5. How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch
  6. BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility
  7. BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting
  8. BioCryst Appoints Steve Aselage to Board of Directors
  9. BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference
  10. BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
  11. Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT
  12. BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up
  13. New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals — Consolidated Revenues, Company Growth, and Expectations for 2018
  14. BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
  15. BioCryst: 3Q Earnings Snapshot